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PREDICTORS OF POOR OUTCOME (HIGH USE OF NON-STEROIDAL
ANTI-INFLAMMATORY DRUGS) AT YEAR 1 FOLLOWING TOTAL
KNEE/HIP ARTHROPLASTY: THE PRESS-UP COHORT STUDY
D. Prieto-Alhambra y,z, A. Judge y,z, M. Javaid y,z, F. Pallisó x, M.
Espallargues k, C. Cooper y,{, N. Arden y,{. yBotnar Res. Ctr., Univ. of
Oxford, Oxford, United Kingdom; z Lifecourse Epidemiology Unit, Univ. of
Southampton, Southampton, United Kingdom; x Traumatology and
Orthopaedics Dept., Santa Maria Hosp., Lleida, Spain; kCatalan Joint
Registry, Catalan Agency for Hlth.Information, Assessment and Quality
(AIAQS), Gen.itat de Catalunya, Barcelona, Spain; {MRC Lifecourse
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Purpose: Implant survival is the most accepted measurement of total
knee (TKA) or hip arthroplasty (THA) results. There is a need for short-
term surrogates for revision for both research andmonitoring purposes.
We have shown that highest utilisation of non-steroidal anti-inﬂam-
matory drugs (NSAIDs) in the ﬁrst year following surgery is related to
increased revision risk, and hence a useful surrogate for “poor
outcome”. We therefore aimed to identify predictors of high NSAID use
at year 1 after TKA and THA surgery.
Methods: Study design and population: We used data from the
Catalan Joint Registry (RACAT), and linked it (85% linked) to comput-
erized primary care records and pharmacy invoice data (SIDIAP
Database). We identiﬁed patients aged >¼40 years undergoing
primary TKA/THA for osteoarthritis registered in the resulting dataset
in the period 1/1/2005-31/07/2012). We excluded patients receiving
revision surgery in the ﬁrst year post-surgery.Ă- Outcome assessment: NSAID utilisation was measured using
pharmacy invoice data, and quantiﬁed in number of Daily
Deﬁned Doses (DDDs) according to the WHO ATC/DDD index.
We classiﬁed patients in the top quintile (percentile 80 and
over) of utilisation as those with a “poor outcome”.
- Potential predictors: we deﬁned a priori a set of predictors of
poor outcome based on previous knowledge and biological
plausibility, including: age, sex, socio-economic status, Charl-
son co-morbidity index, alcohol drinking, smoking status, body
mass index, stroke/TIA, ischaemic heart disease, peripheral
artheriopathy, depression/anxiety disorders, type 2 diabetes
mellitus, previous fracture, chronic kidney failure, COPD, use of
atypical analgesics (gabapentin, pregabalin or trycyclic anti-
depressants) in the previous year, use of NSAIDs in the previous
year.
- Analysis: Backwards stepwise logistic regression (p-entry 0.05,
p-exit 0.1) models were ﬁtted to identify predictors of good
outcome (as deﬁned above).
Results: 22,221 and 10,173 patients undergoing TKA and THA for
osteoarthritis were included. Female sex, lower socio-economic
status, obesity, previous use of atypical analgesics, and amount of
NSAIDs used in the year prior to surgery were associated with “poor
outcome” in both THA and TKA patients [Figure, top and bottom
respectively]. Conversely, Charlson co-morbidity index had an effect
on poorer outcome for TKA patients, and a history of depression/
anxiety disorders was related to poorer outcome following THA, but
had no signiﬁcant effect on the other subpopulation.
Conclusions:We report for the ﬁrst time on a set of predictors of “poor
outcome” as deﬁned on the basis of NSAID usage during the ﬁrst year
following TKA surgery. A predictive tool can be built using these in order
to target patients who would beneﬁt the least from this surgical
procedure. A validated version of such tool would be of interest for
patients, clinicians and health-care managers.
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BISPHOSPHONATE USE AND IMPROVED IMPLANT SURVIVAL: A
NATION-WIDE COHORT STUDY
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Purpose: Osteolysis and aseptic loosening are the most common cause
of revision arthroplasty worldwide. Bisphosphonates might improve
implant survival through their anti-osteoclast effects. We aimed to
study the association between bisphosphonate use and implant
survival.
Methods: A retrospective cohort study was conducted within the
Danish nationwide registries (5.5 million residents). We identiﬁed
patients aged >¼40 years undergoing total joint replacement (TJR)
during the study period (1998-2007) using ICD10 codes. Patients with
inﬂammatory arthritides, bone Paget, hip fracture and use of DMARDs
were excluded. Each participant was followed up until end of study,
date of emigration, revision surgery, or patient's death, whichever came
ﬁrst. Participants were classiﬁed as bisphosphonate users (BPU) if they
had been on treatment for at least 6 months. A time-varying exposure
was used to avoid immortal-time bias. Up to six BP non-users (BPNU)
undergoing arthroplasty were matched to each BPU using propensity
scores. Stratiﬁed Cox regression was used to model implant survival
according to bisphosphonate use. Further, we studied the association
between duration of use, adherence (medication possession
ratio¼MPR), and timing of therapy initiation (pre-op vs post-op) and
implant survival. Finally, we tested for a-priori deﬁned interactions
Table 1
Biomarkers Hazard Ratio (95% CI)
uNTX-I 1.80 (0.83, 3.90
uCTX-II 2.28 (1.00, 5.16)
uC2C 1.06 (0.57, 1.97)
uC1,2C 1.29 (0.88, 1.89)
sHA 1.44 (0.79, 2.63)
sCS846 1.32 (0.49, 3.56)
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S156between BP use and age, sex, joint replaced (hip/knee), and prior frac-
ture on outcome by introducing multiplicative terms in the equation.
Results: 80,342/95,392 (84.2%) subjects were eligible. We identiﬁed
1,950 (2.4%) BPU, and 1,911 (98.0%) of them were matched to 10,755
BPNU. In total, 226/12,666 (1.78%) of the participants (22/1,911 BPU and
204/10,755 matched BPNU) underwent revision surgery during study
follow-up (median 1.11 years, inter-quartile range 0.43-2.29 years).
Cox regression models showed reduced revision risk in BP users
(propensity-matched HR 0.59; 95% Conﬁdence Interval (CI) [0.37-0.94])
[Figure], which remained signiﬁcant after multivariable adjustment for
unbalanced covariates (adjusted HR 0.59; 95% CI [0.37-0.93]). This
protective effect was only seen in BPU who initiated treatment post-
operatively (adjusted HR 0.36 ; 95% CI [0.15-0.84]) and not in those
starting pre-op (adjusted HR 0.77; 95% CI [0.44-1.35]), and who
remained on treatment for at least one year: adjusted HR 0.50; 95% CI
[0.27-1.00] for those treated for 1-2 years compared to adjusted HR
1.29; 95% CI (0.80-2.08) in those treated for 6-12 months. Patients with
the highest adherence beneﬁted the most (adjusted HR 0.53; 95% CI
(0.30-0.95)) in BPU with MPR>0.8).
The effect of BPU on implant survival was not modiﬁed by age, gender,
fracture history or joint replaced (all p for interactions>0.2).
Conclusions: BPU are at 40% reduced risk of revision compared to
matched BPNU. These results are similar to previous ﬁndings using
similar retrospective data from the UK [Prieto-Alhambra D et al. BMJ
2011]. Conﬁrmation of these beneﬁcial effects in formal randomized
controlled trials is urgently needed.Ă
sCPII 0.58 (0.34, 0.99)
sCOMP 2.58 (0.48, 13.90)
sC2C 0.53 (0.15, 1.87)
sC1,2C 1.61 (0.52, 4.94)
uCTX-II/sCPII 1.78 (1.17, 2.72)
uC2C/sCPII 1.44 (0.93, 2.21)
uC1,2C/sCPII 1.52 (1.08, 2.16)
sC2C/sCPII 2.15 (1.05, 4.39)293
ASSOCIATION OF BIOMARKERS WITH OSTEOARTHRITIS
PROGRESSION BASED ON MRI: RESULTS FROM THE VANCOUVER
KNEE OSTEOARTHRITIS PROGRESSION (KOAP) STUDY
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Purpose: To determine the association of biomarkers with progression
of osteoarthritis (OA), based on MRI, in a population-based cohort of
predominantly pre-radiographic disease.
Methods: Population-based longitudinal cohort study of subjects, age
40 to 79, with knee pain. Subjects were evaluated at baseline and
follow-up (FU) using detailed clinical assessments, knee x-ray, MRI
(1.5T) and biomarkers. MRI of cartilage (MRC) was scored 0-4 on six
joint surfaces. Progression was deﬁned on MRI as an increase in MRC
score of 1 grade on at least 2 cartilage surfaces or an increase of MRC
score of 2 grades on at least 1 cartilage surface. Urine biomarkers
included C-telopeptide of type II collagen (uCTX-II) (Nordic Bioscience),
type II and type I and II collagen cleavage neoepitopes (uC2C, uC1,2C)
(Ibex), N-telopeptide of type I collagen (uNTX-I) (Ostex). Serum
biomarkers included sC1,2C, sC2C, c-propeptide of type II procollagen(sCPII), 846 epitope (sCS846) (Ibex), cartilage oligomeric matrix protein
(sCOMP) (AnaMar) and hyaluronic acid (sHA) (Corgenix). Ratios of type
II collagen degradation with synthesis markers were also evaluated.
Biomarker data were log transformed. Exponential regression analysis
was used to determine the association of each biomarker with OA
progression, adjusted for age, gender, BMI and joint count. All analyses
utilized longitudinal stratum sampling weights to ensure generaliz-
ability of results.
Results: Of 255 subjects seen at baseline, 163 (63.9%) were assessed at
a median FU of 3.2 years (range 2.5-5.1). Of these, 60.6% had KL grade
<2, mean age was 57.6 years. MRI progression was present in 15.5% of
subjects. Biomarkers signiﬁcantly associated with OA progression
included uCTX-II (HR 2.28; 95% CI 1.00, 5.16), sCPII (HR 0.58; 95% CI 0.34,
0.99), as well as ratios of uCTX-II/sCPII (HR 1.78; 95% CI 1.17, 2.72),
uC1,2C/sCPII (HR 1.52; 95% CI 1.08, 2.16) and sC2C/sCPII (HR 2.15; 95% CI
1.05, 4.39) (Table 1).Conclusions: In this population-based cohort of predominantly pre-
radiographic knee OA, uCTX-II and sCPII were both signiﬁcantly asso-
ciated with OA progression. As well, ratios of uCTX-II/sCPII, uC1,2C/sCPII
and sC2C/sCPII were signiﬁcantly associated with OA progression with
similar strengths of association. These biomarkers may be useful in
future studies aimed at evaluating OA disease progression in epidemi-
ologic studies and clinical trials.
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SIMPLIFIED CLINICAL PREDICTION MODEL FOR OSTEOARTHRITIS
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KNEE OSTEOARTHRITIS PROGRESSION (KOAP) STUDY
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Purpose: To determine the clinical predictors of osteoarthritis (OA)
progression based on cartilage damage on MRI in a population-based
cohort of predominantly pre-radiographic knee OA and to develop
a simpliﬁed model to identify those at risk of progression with high
speciﬁcity for practical application in clinical trials.
Methods: Population-based longitudinal cohort study of subjects, age
40 to 79, with knee pain. Subjects were evaluated at baseline and
follow-up (FU) using detailed clinical assessments, standardized knee
examination, ﬁxed-ﬂexion knee x-ray and MRI (1.5T). X-rays were read
for Kellgren-Lawrence (KL) 0-4 grade. MRI of cartilage (MRC) was
scored 0-4 on six joint surfaces by a blinded reader. OA progression was
deﬁned on MRI as an increase in MRC score of 1 grade on at least 2
cartilage surfaces or an increase in MRC score of 2 grades on at least 1
cartilage surface. Exponential regression analysis was used to develop
a prediction model for OA progression. The model was evaluated based
on prediction accuracy, Akaike's Information Criterion (AIC) and C-
index, where a 1.0 score indicates a perfect model ﬁt. The model was
then simpliﬁed by removing variables and evaluating the impact on the
model accuracy and C-index. All analyses utilized longitudinal stratum
sampling weights to maintain generalizability.
Results: Of 255 subjects seen at baseline, 163 (63.9%) were assessed at
a median FU of 3.2 years (range 2.5-5.1). Of these, 60.6% had KL grade
